Table 11.
Series of meningiomas and respective percentages of p53 expression.
| Authors, year, country | p53 % | Observations |
|---|---|---|
| Current paper | 92.6 | 96 grade I. No relation with PR |
| Das et al., 2000, Thailand (99) | 5.0 grade I | 15% in grades I and II |
| Das et al., 2002, Thailand (76) | 14.0 | MDM2 expression in 46. Combination of p53 and MDM2 correlated with PR+ |
| Lanzafame et al., 2000, Italy (100) | 57.0 | 69 grades I, II, and III. Greater in grades II and III |
| Amatya et al., 2001, Japan (101) | 19.8 | 146 cases. Grade I < grade II < grade III |
| Yang et al., 2008, South Korea (102) | 10.0 grade I | 25% in grade II and 79% in grade III |
| Kärjä et al., 2010, Finland/Sweden (13) | 59 grade I. Primary, 3.2 ± 1.5%; recurrent, 6.5 ± 3.6%; p = 0.889 | |
| Abdelzaher et al., 2011, Egypt (51) | 6.63 grade I | 60 grade I |
| Pavelin et al., 2013, Croatia (31) | 170 cases. No relation with tumor grade. 10–88% of p53 in the literature |
|
| Trott et al., 2015, Brazil (6) | 46.8 grade I | 141 grades I; 13 grades II (84.6%); 3 grades III (33.3%); p > 0.05 |
| Fukami et al., 2016, Japan/Germany (104) | 47.5 | 52 grade I, 3 grade II and 4 grade III |
PR, progesterone receptor; MDM2, mouse double minute 2 homolog.